مورد إلكتروني
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
| العنوان: | Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. |
|---|---|
| المؤلفون: | Gul, Anita |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology; vol 38, iss 27, 3088-3094; 0732-183X |
| بيانات النشر: | eScholarship, University of California 2020-09-01 |
| تفاصيل مُضافة: | Gul, Anita Stewart, Tyler F Mantia, Charlene M Shah, Neil J Gatof, Emily Stern Long, Ying Allman, Kimberly D Ornstein, Moshe C Hammers, Hans J McDermott, David F Atkins, Michael B Hurwitz, Michael Rini, Brian I |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | PurposeImmune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC after prior treatment with anti-PD-1 pathway-targeted therapy.Patients and methodsPatients with metastatic RCC who received prior anti-PD-1 pathway-targeted therapy and subsequently received ipilimumab and nivolumab were reviewed. Objective response rate and progression-free survival per investigator assessment were recorded. Toxicity of ipilimumab and nivolumab was also assessed.ResultsForty-five patients with metastatic RCC were included. All patients (100%) received prior ICIs targeting the PD-1 pathway. The median age was 62 years (range, 21-82 years). At a median follow-up of 12 months, the objective response rate to ipilimumab and nivolumab was 20%. The median progression-free survival while on ipilimumab and nivolumab was 4 months (range, 0.8-19 months). Immune-related adverse events (irAEs) of any grade with ipilimumab and nivolumab were recorded in 29 (64%) of the 45 patients; grade 3 irAEs were recorded in 6 (13%) of the 45 patients.ConclusionIpilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic RCC who had prior treatment with checkpoint inhibition. |
| مصطلحات الفهرس: | Humans, Carcinoma, Renal Cell, Kidney Neoplasms, Disease Progression, Antineoplastic Combined Chemotherapy Protocols, Salvage Therapy, Retreatment, Retrospective Studies, Adult, Aged, 80 and over, Middle Aged, Female, Male, Young Adult, Programmed Cell Death 1 Receptor, Ipilimumab, B7-H1 Antigen, Nivolumab, Progression-Free Survival, Immune Checkpoint Inhibitors, Kidney Disease, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Good Health and Well Being, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis, article |
| URL: | |
| الإتاحة: | Open access content. Open access content public |
| ملاحظة: | application/pdf Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol 38, iss 27, 3088-3094 0732-183X |
| أرقام أخرى: | CDLER oai:escholarship.org:ark:/13030/qt5n52s9tp qt5n52s9tp https://escholarship.org/uc/item/5n52s9tpTest https://escholarship.orgTest/ 1391599742 |
| المصدر المساهم: | UC MASS DIGITIZATION From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1391599742 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |